File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/cid/ciab630
- Scopus: eid_2-s2.0-85124577112
- PMID: 34260716
- WOS: WOS:000754315700027
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Title | Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection |
---|---|
Authors | |
Keywords | asymptomatic infection seroconversion symptomatic COVID-19 viral RNA waning efficacy |
Issue Date | 2022 |
Citation | Clinical Infectious Diseases, 2022, v. 74, n. 3, p. 544-552 How to Cite? |
Abstract | Although interim results from several large, placebo-controlled, phase 3 trials demonstrated high vaccine efficacy (VE) against symptomatic coronavirus disease 2019 (COVID-19), it is unknown how effective the vaccines are in preventing people from becoming asymptomatically infected and potentially spreading the virus unwittingly. It is more difficult to evaluate VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than against symptomatic COVID-19 because infection is not observed directly but rather is known to occur between 2 antibody or reverse-transcription polymerase chain reaction (RT-PCR) tests. Additional challenges arise as community transmission changes over time and as participants are vaccinated on different dates because of staggered enrollment of participants or crossover of placebo recipients to the vaccine arm before the end of the study. Here, we provide valid and efficient statistical methods for estimating potentially waning VE against SARS-CoV-2 infection with blood or nasal samples under time-varying community transmission, staggered enrollment, and blinded or unblinded crossover. We demonstrate the usefulness of the proposed methods through numerical studies that mimic the BNT162b2 phase 3 trial and the Prevent COVID U study. In addition, we assess how crossover and the frequency of diagnostic tests affect the precision of VE estimates. |
Persistent Identifier | http://hdl.handle.net/10722/334807 |
ISSN | 2023 Impact Factor: 8.2 2023 SCImago Journal Rankings: 3.308 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lin, Dan Yu | - |
dc.contributor.author | Gu, Yu | - |
dc.contributor.author | Zeng, Donglin | - |
dc.contributor.author | Janes, Holly E. | - |
dc.contributor.author | Gilbert, Peter B. | - |
dc.date.accessioned | 2023-10-20T06:50:53Z | - |
dc.date.available | 2023-10-20T06:50:53Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Clinical Infectious Diseases, 2022, v. 74, n. 3, p. 544-552 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | http://hdl.handle.net/10722/334807 | - |
dc.description.abstract | Although interim results from several large, placebo-controlled, phase 3 trials demonstrated high vaccine efficacy (VE) against symptomatic coronavirus disease 2019 (COVID-19), it is unknown how effective the vaccines are in preventing people from becoming asymptomatically infected and potentially spreading the virus unwittingly. It is more difficult to evaluate VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than against symptomatic COVID-19 because infection is not observed directly but rather is known to occur between 2 antibody or reverse-transcription polymerase chain reaction (RT-PCR) tests. Additional challenges arise as community transmission changes over time and as participants are vaccinated on different dates because of staggered enrollment of participants or crossover of placebo recipients to the vaccine arm before the end of the study. Here, we provide valid and efficient statistical methods for estimating potentially waning VE against SARS-CoV-2 infection with blood or nasal samples under time-varying community transmission, staggered enrollment, and blinded or unblinded crossover. We demonstrate the usefulness of the proposed methods through numerical studies that mimic the BNT162b2 phase 3 trial and the Prevent COVID U study. In addition, we assess how crossover and the frequency of diagnostic tests affect the precision of VE estimates. | - |
dc.language | eng | - |
dc.relation.ispartof | Clinical Infectious Diseases | - |
dc.subject | asymptomatic infection | - |
dc.subject | seroconversion | - |
dc.subject | symptomatic COVID-19 | - |
dc.subject | viral RNA | - |
dc.subject | waning efficacy | - |
dc.title | Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1093/cid/ciab630 | - |
dc.identifier.pmid | 34260716 | - |
dc.identifier.scopus | eid_2-s2.0-85124577112 | - |
dc.identifier.volume | 74 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 544 | - |
dc.identifier.epage | 552 | - |
dc.identifier.eissn | 1537-6591 | - |
dc.identifier.isi | WOS:000754315700027 | - |